42141-50-4

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrazol-5-amine, 1-(2-chlorophenyl)-3-methylis used as a building block for the synthesis of biologically active compounds for various therapeutic applications. Its unique structural features, including the amino and chlorophenyl groups, make it a promising candidate for the development of new drugs with enhanced biological properties.
Used in Agrochemical Industry:
1H-Pyrazol-5-amine, 1-(2-chlorophenyl)-3-methylis used as a starting material for the synthesis of agrochemicals with potential pesticidal or herbicidal activities. Its structural features can be further modified to improve its efficacy and selectivity in controlling pests or weeds, contributing to more sustainable agricultural practices.

Upstream product

• 1118-61-2 3-Aminocrotononitrile 
• 95-51-2 o-chloroaniline 
• 10449-07-7 (2-chlorophenyl)hydrazine 
• 41052-75-9 o-chlorophenylhydrazine hydrochloride 

Downstream Products

• 86817-20-1 1-(2'-chloro)phenyl-3-methyl-4-thiocyanto-5-aminopyrazole 
• 105438-67-3 5-Acetamido-1-(2-chlorophenyl)-3-methylpyrazole 
• 105438-68-4 5-Benzamido-1-(2-chlorophenyl)-3-methylpyrazole 
• 81212-52-4 1-(2'-cloro)fenil-3-metil-4-nitroso-5-amminopirazolo 
• 1026908-22-4 2-{[2-(2-chloro-phenyl)-5-methyl-2H-pyrazol-3-ylamino]-methylene}-malonic acid diethyl ester 
• 1380573-49-8 4-(4-phenoxyphenyl)-3,6-dimethyl-1-(2-chlorophenyl)-4,8-dihydro-1H-pyrazolo[3,4-e][1,4]thiazepin-7-one 
• 1210047-32-7 methyl 2-((1-(2-chlorophenyl)-3-methyl-1H-pyrazol-5-yl)amino)-5-methoxybenzoate 
• 105438-98-0 Benzyl-[2-(2-chloro-phenyl)-5-methyl-4-nitroso-2H-pyrazol-3-yl]-amine 
• 105438-56-0 1-(2-Chloro-phenyl)-3-methyl-5-phenyl-1,6-dihydro-imidazo[4,5-c]pyrazole 
• 105438-97-9 1-(2-Chlorophenyl)-5-ethylamino-3-methyl-4-nitrosopyrazole 
• 105438-83-3 5-Benzylamino-1-(2-chlorophenyl)-3-methylpyrazole 
• 105438-55-9 1-(2-Chloro-phenyl)-3,5-dimethyl-1,6-dihydro-imidazo[4,5-c]pyrazole 

Relevant academic research and scientific papers

One-pot, telescoped synthesis of N-aryl-5-aminopyrazoles from anilines in environmentally benign conditions

An efficient synthetic approach to synthesize N-aryl-5-aminopyrazoles from anilines via a one-pot, telescoped reaction performed in entirely aqueous conditions has been developed. This protocol provides a rapid, convenient method to prepare N-aryl-5-aminopyrazoles, useful building blocks for the synthesis of several bicyclic nitrogen heterocycles, by avoiding the isolation of the toxic intermediate arylhydrazines and the use of a metallic reductant. The Royal Society of Chemistry 2014.

Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists

A virtual screening procedure was applied to the discovery of structurally diverse non-steroidal Farnesoid X Receptor (FXR) agonists. From 117 compounds selected by virtual screening, a total of 47 compounds were found to be FXR agonists, with 34 of them showing activity below a concentration of 20 μM. 1H-Pyrazole[3,4-e][1,4]thiazepin-7-one-based hit compound 7 was chosen for hit-to-lead optimization. A large number of 1H-pyrazole[3,4-e][1,4]thiazepin-7- one derivatives was designed, synthesized, and evaluated by a cell-based luciferase transactivation assay for their agonistic activity against FXR. Most of them exhibited low micromolar range of potency and very high efficacy.

Identification and optimization of substituted 5-aminopyrazoles as potent and selective adenosine A1 receptor antagonists

Potent and selective adenosine A1 receptor antagonists were disclosed. SAR and pharmacological profile of selected compounds were discussed.

Discovery of new orally active phosphodiesterase (PDE4) inhibitors

A series of 4-anilinopyrazolopyridine derivatives were synthesized and biologically evaluated as inhibitors of phosphodiesterase (PDE4). Chemical modification of 3, a structurally new chemical lead that was found in our in-house library, was focused on 1- and 3-substituents. Full details of the discovery of a new orally active chemical lead 5 are presented. Structure-activity relationship data, pharmacological evaluation, and the subtype selectivity study are also presented.